Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts selected from sodium, potassium, calcium, and magnesium salts. The BHB composition may also include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, a short-, medium-, or long-chain fatty acid source, vitamins, minerals, flavorants, or other excipients.

Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts selected from sodium, potassium, calcium, and magnesium salts. The BHB composition may also include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, a short-, medium-, or long-chain fatty acid source, vitamins, minerals, flavorants, or other excipients.

The present invention relates to synthetic nutritional compositions, especially infant formula compositions, with a low content of medium-chain fatty acids (or MFCAs) and particularly in specific proportions. The invention also relates to the use of said compositions to promote liver and/or gut maturation in infants or young children and/or to reduce the risk of liver and/or gut disease in infants or young children.

The present invention relates to synthetic nutritional compositions, especially infant formula compositions, with a low content of medium-chain fatty acids (or MFCAs) and particularly in specific proportions. The invention also relates to the use of said compositions to promote liver and/or gut maturation in infants or young children and/or to reduce the risk of liver and/or gut disease in infants or young children.

The present invention concerns a nutritional composition, for example a synthetic nutritional composition, for use in reducing the metabolic stress. This composition is for use in mammals, preferably in humans, more preferably in infants. The nutritional composition comprises one or more medium chain fatty acid (MCFA) derivative or derivatives for use in reducing metabolic stress. Conditions and/or diseases associated to the metabolic disorders and/or imbalances in an infant are selected in the group consisting of neurological, growth and/or gut retarded development or abnormalities, hypoglycemia, hyperglycemia, hyperinsulinemia, hypertriglyceridemia. The infant is born preterm or with low-birthweight (LBW) or who experienced intra-uterine growth retardation (IUGR) or small for gestational age (SGA)).

The present invention concerns a nutritional composition, for example a synthetic nutritional composition, for use in reducing the metabolic stress. This composition is for use in mammals, preferably in humans, more preferably in infants. The nutritional composition comprises one or more medium chain fatty acid (MCFA) derivative or derivatives for use in reducing metabolic stress. Conditions and/or diseases associated to the metabolic disorders and/or imbalances in an infant are selected in the group consisting of neurological, growth and/or gut retarded development or abnormalities, hypoglycemia, hyperglycemia, hyperinsulinemia, hypertriglyceridemia. The infant is born preterm or with low-birthweight (LBW) or who experienced intra-uterine growth retardation (IUGR) or small for gestational age (SGA)).

A mixture (M) comprising or, alternatively consisting of: (i) water-soluble oligosaccharide, or a water-soluble complex carbohydrate, or mixtures thereof; (II) a casein; (ill) n3 and/or n6 fatty acids; (iv) an extract of Vaccinium macrocarpon. The present invention further relates to a pharmaceutical composition, or a food for special medical purpose (FSMP), or a medical device formulation or composition, or a dietary supplement comprising the aforementioned mixture (M), for use as medicament, or for use in the treatment of a chronic inflammatory bowel disease, in particular of states of malnutrition in subjects suffering from said chronic inflammatory bowel disease.

A mixture (M) comprising or, alternatively consisting of: (i) water-soluble oligosaccharide, or a water-soluble complex carbohydrate, or mixtures thereof; (II) a casein; (ill) n3 and/or n6 fatty acids; (iv) an extract of Vaccinium macrocarpon. The present invention further relates to a pharmaceutical composition, or a food for special medical purpose (FSMP), or a medical device formulation or composition, or a dietary supplement comprising the aforementioned mixture (M), for use as medicament, or for use in the treatment of a chronic inflammatory bowel disease, in particular of states of malnutrition in subjects suffering from said chronic inflammatory bowel disease.

Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts selected from sodium, potassium, calcium, and magnesium salts. The BHB composition may also include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, one or more ketone precursors, supplements, or other compounds that cause a rise in blood ketone levels without adding more electrolytes to the bloodstream, a short-, medium-, or long-chain fatty acid source, vitamins, minerals, flavorants, or other excipients.

Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts selected from sodium, potassium, calcium, and magnesium salts. The BHB composition may also include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, one or more ketone precursors, supplements, or other compounds that cause a rise in blood ketone levels without adding more electrolytes to the bloodstream, a short-, medium-, or long-chain fatty acid source, vitamins, minerals, flavorants, or other excipients.